FY2022 · ended Dec 31, 2022 · Revenue $0, -100.0% YoY · Filed Mar 6, 2025
Alx Oncology Holdings Inc (ALXO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$84.4 million. As of Jun 30, 2026 it held $153.4 million in cash and investments and $11.5 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-101.69M
+24.6% vs prior year
Operating cash flow (TTM)
$-70.78M
+32.9% vs year-ago TTM
Free cash flow (TTM)
$-70.95M
+32.9% vs year-ago TTM
EPS
$-1.90
+26.4% vs prior year
Dividend per share
None
Shares outstanding
131.61M
+146.5% vs prior year
Net cash
$141.84M
as of Jun 30, 2026
Operating margin
-3694.0%
FY 2020
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALXO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1810182
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | — |
| Operating income | -$104.0M | -$142.5M | -$170.3M | -$127.4M | -$83.6M |
| Net income | -$101.7M | -$134.8M | -$160.8M | -$123.5M | -$83.5M |
| Diluted EPS | -$1.90 | -$2.58 | -$3.74 | -$3.03 | — |
| Operating cash flow | -$84.1M | -$121.9M | -$130.4M | -$89.2M | -$68.1M |
| Free cash flow | -$84.4M | -$122.4M | -$131.6M | -$90.7M | -$68.8M |
| Total assets | $59.0M | $147.8M | $242.6M | $306.5M | $380.2M |
| Total liabilities | $33.1M | $34.2M | $52.8M | $43.0M | $17.1M |
| Stockholders' equity | $26.0M | $113.6M | $189.7M | $263.5M | $363.0M |
| Cash and investments | $48.3M | $131.3M | $218.1M | $282.9M | $363.7M |
| Total debt | $15.2M | $17.7M | $18.2M | $16.9M | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 15, 2026 | Oct 14, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Jun 30, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
All 421 Alx Oncology Holdings Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.